VIVIBEN
LIVE

Serial Number

79348594

Owner

FRAU PHARMA S.R.L.

Attorney

Keith A. Weltsch

Filing Date

Feb 8, 2022

Add to watchlist:

No watchlists yet
View on USPTO

VIVIBEN Trademark

Serial Number: 79348594 • Registration: 7923960

VIVIBEN is a trademark filed by FRAU PHARMA S.R.L. on February 8, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 29 (Meats & Processed Foods), Class 30 (Staple Foods). The application is currently registered and active.

Owner Contact Info

FRAU PHARMA S.R.L. (5 trademarks)

Via Trivulzina, 13/1

Entity Type: 16

Trademark Details

Filing Date

February 8, 2022

Registration Date

September 2, 2025

Published for Opposition

July 15, 2025

Goods & Services

Animal fats for food; blended oil for food; soya milk; yogurt; breakfast yogurt; milk; cheese; fermented milk; goat milk; powdered milk; processed shell fruits; condensed milk; food products made from meat, fish, poultry and game, namely, meat-based snack foods, fish-based snack foods; food products made from fruits and vegetables, namely, dried fruits and vegetables, preserved fruits and vegetables, cooked fruits and vegetables; all of the foregoing goods featuring palmithoylethanolamide, oleoylethanolamide, anandamide, poliamines, namely, spermidine, spermine, phosphatidylserine, being added, alone and natural phospholipid in combination with the aforementioned goods; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CBD

Nutraceuticals for use in therapeutical diets, for the treatment of inflammation, cardiological conditions, diabetes, obesity or overweight people; nutraceuticals for use as dietary supplements; vitamin preparations; dietetic foods, namely, bakery goods adapted for medical purposes; wheat germ dietary supplements; dietary supplements for animals; food supplements containing folic acid, methyltetrahydrofolic acid, L (-) methyl tetraidofolic acid and its salts; nutraceutical preparations for medical purposes, to be used to improve the quality of life of oncological patients, namely, for the treatment of cancer; pharmaceutical products for use by human beings, namely, ocular pharmaceuticals; veterinary products, namely, dietary supplement nutraceuticals, amino acids and biological preparations for veterinary purposes for the treatment of cancer; dietetic foods adapted for medical use; dietary supplements for human beings and animals; dietary food supplements for medical use containing oleoylethanolamide, palmithoylethanolamide, anandamide, spermidine, spermine, phosphatidylserine, natural phospholipids, L (-) methyltetrahydrofolic acid and its salts, added or enriched with the above chemical nutrients to improve the nutritional value or the health benefits, eventually added with other products excipients, and processing aids used in human or animal diet; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CBD

Chemical additives for use in the manufacture of food products; vitamins for use in the manufacture of food products; chemical additives for use in the manufacture of food as enrichment of food composition; vitamins for use in the manufacture of food as enrichment of food composition; chemical products, namely, chemical additives to be used in the manufacture of food supplements; chemical products, namely, chemical additives to be used in the manufacture of pharmaceuticals and veterinary products; vitamins to be used in the manufacture of pharmaceutical and veterinary products; oleoylethanolamide to be used in the production of food and reinforced food; oleoylethanolamide to be used in the production of pharmaceutical and veterinary products; oleoylethanolamide to be used in the production of medical food; oleoylethanolamide to be used in the production of dietary ingredients in the nature of dietary supplements and food supplements; oleoylethanolamide and palmitoylethanolamide combination for use in the production of pharmaceutical and veterinary products; oleoylethanolamide and palmitoylethanolamide combination for use in the production of food and medical food; oleoylethanolamide and palmitoylethanolamide combination for use in the production of food supplements; oleoylethanolamide and palmitoylethanolamide combination used in the manufacture of dietary ingredients in the nature of dietary supplements; anandamide for use in the production of medical food; anandamide for use in the production of food supplements; anandamide for use in the production of pharmaceutical products; combination of oleoylethanolamide, palmitoylethanolamide, anandamide for use in the production of food, medical food, food supplements, dietary ingredients, pharmaceutical and veterinary products; anandamide with purity from 10 percent to 99 percent for use in the production of food, medical food, food supplements, dietary ingredients, pharmaceutical and veterinary products; oleoylethanolamide with purity from 10 percent to 99 percent for use in the production of food, medical food, food supplements, dietary ingredients, pharmaceutical and veterinary products; spermidine, spermine, aliphatic polyamine used in the production of food and medical food; spermidine, spermine, aliphatic polyamine to be used in the production of pharmaceutical and veterinary products; spermidine, spermine, aliphatic polyamine used in the production of food supplements and dietary ingredients; spermidine, spermine, aliphatic polyamine used in the manufacture of food to reinforce or enrich food, food extract and fermented food; polyamines and acyl ethalonammides combination for use in the production of food, food supplements, pharmaceuticals, dietary products in the nature of dietary supplements; phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylenositol as single entity to be used in the manufacture of food, medical food, food supplements, pharmaceutical, veterinary products; natural phospholipids (PS, PC, PE, PI) and acyl ethanolammides combination in powder form and in oil dispersion or emulsion for use in the manufacture of medical food, food supplements; combination of natural phospholipids (PS, PC, PE,PI), spermidine, spermine in powder form and in oil dispersion or emulsion for use in the manufacture of medical food, food supplements; combination of natural phospholipids (PS, PC, PE, PI), L (-) methyl tetraidofolic acid or its salts in powder and fluid form for use in the manufacture of medical food, food supplements; natural lecithynes added with spermidine, spermine and other natural aliphnatic polyamines in powder and oil form for use in the manufacture of medical food, food supplements; natural lecithynes added with L (-) methyl tetraidofolic acid and or folic acid in powder and oil form for use in the manufacture of medical food, food supplements; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CBD

Chocolate; ice cream; biscuits; breakfast cereals; pizzas; bakery goods; rice; popcorn; soya flour; starch-based thickeners for whipped cream; flour; bread; pastries; frozen confectionery; fruit jellies being candies; baking powder; cooking salt; food products made from rice, flour and cereals, namely, rice, flour and processed cereals with added folic acid, methyltetrahydrofolic acid, L (-) methyltetrahydrofolic acid and its salts, and folic acid derivates; food products being pastry, petit fours and confectionery made of sugar; all of the foregoing goods featuring palmithoylethanolamide, oleoylethanolamide, anandamide, poliamines, namely, spermidine and spermine phosphatidylserine, being added, alone, and natural phospholipid in combination with the aforementioned goods; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CB

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 2, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 16, 2026 FICS
FINAL DISPOSITION PROCESSED
Mar 16, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 2, 2025 FICR
POST PUBLICATION AMENDMENT – NOT ENTERED
Oct 7, 2025 CHPN
ASSIGNED TO PETITION STAFF
Oct 6, 2025 APET
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 2, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 2, 2025 R.PR
TEAS POST PUBLICATION AMENDMENT RECEIVED
Aug 26, 2025 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 15, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 15, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 9, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 12, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 12, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 12, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 12, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 12, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2025 TROA
REFUSAL PROCESSED BY IB
Dec 21, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 3, 2024 RFCS
REFUSAL PROCESSED BY MPU
Dec 3, 2024 RFRR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 26, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 7, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 7, 2024 OPNR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 14, 2023 RFCR
NON-FINAL ACTION WRITTEN
Aug 14, 2023 CNRT
ASSIGNED TO EXAMINER
Jan 17, 2023 DOCK
ASSIGNED TO EXAMINER
Dec 8, 2022 DOCK
ASSIGNED TO EXAMINER
Nov 21, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 13, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 7, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 6, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 1, 2022 REPR